Which has higher valuation & earnings, ATHX or ORGS?

Orgenesis has higher revenue and earnings than Athersys. Orgenesis is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athersys $146K 0.00 -$72.53M -$2.03 N/A Orgenesis $662K 3.87 -$55.36M -$11.51 N/A

Is ATHX or ORGS more profitable?

Athersys has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Orgenesis -3,827.81% N/A -130.18%

Do analysts recommend CANF or ATHX?

Can-Fite BioPharma presently has a consensus target price of $42.50, indicating a potential upside of 1,391.23%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Can-Fite BioPharma is more favorable than Athersys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CANF or ATHX more profitable?

Company Net Margins Return on Equity Return on Assets Can-Fite BioPharma N/A N/A N/A Athersys N/A N/A -223.03%

Which has higher valuation & earnings, ATHX or VCNX?

Vaccinex has higher revenue and earnings than Athersys. Vaccinex is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athersys $146K 0.00 -$72.53M -$2.03 N/A Vaccinex $388K 7.30 -$20.25M -$48.27 N/A

Is ATHX or VCNX more profitable?

Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Vaccinex N/A N/A -383.58%

Is ATHX or BPTH more profitable?

Athersys' return on equity of 0.00% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Bio-Path N/A -2,842.40% -337.48%

Which has better valuation & earnings, ATHX or GRAY?

Graybug Vision has higher revenue and earnings than Athersys. Graybug Vision is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athersys $146K 0.00 -$72.53M -$2.03 N/A Graybug Vision $426.96M 0.00 -$35.60M -$24.23 N/A

Is ATHX or GRAY more profitable?

Athersys' return on equity of 0.00% beat Graybug Vision's return on equity. Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Graybug Vision N/A -77.61% -71.34%

Athersys (ATHX) Competitors

Compare

ATHX vs. ORGS, CANF, VCNX, BPTH, and GRAY

Should you buy Athersys stock or one of its competitors? MarketBeat compares Athersys with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Athersys include Orgenesis (ORGS), Can-Fite BioPharma (CANF), Vaccinex (VCNX), Bio-Path (BPTH), and Graybug Vision (GRAY). These companies are all part of the "pharmaceutical preparations" industry.

How does Athersys compare to Orgenesis?

Athersys (NASDAQ:ATHX) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Athersys has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Orgenesis	-3,827.81%	N/A	-130.18%

19.4% of Athersys shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 0.0% of Athersys shares are owned by company insiders. Comparatively, 1.9% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Athersys' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
Athersys	Neutral
Orgenesis	Neutral

Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the broader market. Comparatively, Orgenesis has a beta of 2.89, indicating that its share price is 189% more volatile than the broader market.

Orgenesis has higher revenue and earnings than Athersys. Orgenesis is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Orgenesis	$662K	3.87	-$55.36M	-$11.51	N/A

Summary

Orgenesis beats Athersys on 6 of the 9 factors compared between the two stocks.

How does Athersys compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Athersys	N/A	N/A	-223.03%

Can-Fite BioPharma has higher revenue and earnings than Athersys. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	4.61	-$7.63M	-$35.80	N/A
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A

In the previous week, Can-Fite BioPharma had 1 more articles in the media than Athersys. MarketBeat recorded 1 mentions for Can-Fite BioPharma and 0 mentions for Athersys. Can-Fite BioPharma's average media sentiment score of 0.00 equaled Athersys'average media sentiment score.

Company	Overall Sentiment
Can-Fite BioPharma	Neutral
Athersys	Neutral

Can-Fite BioPharma has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Athersys has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market.

Can-Fite BioPharma presently has a consensus target price of $42.50, indicating a potential upside of 1,391.23%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Can-Fite BioPharma is more favorable than Athersys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 19.4% of Athersys shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Comparatively, 0.0% of Athersys shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Can-Fite BioPharma beats Athersys on 10 of the 12 factors compared between the two stocks.

How does Athersys compare to Vaccinex?

Athersys (NASDAQ:ATHX) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Vaccinex has higher revenue and earnings than Athersys. Vaccinex is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Vaccinex	$388K	7.30	-$20.25M	-$48.27	N/A

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Vaccinex	N/A	N/A	-383.58%

Athersys has a beta of -0.9, suggesting that its share price is 190% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

In the previous week, Athersys' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
Athersys	Neutral
Vaccinex	Neutral

19.4% of Athersys shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 0.0% of Athersys shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Vaccinex beats Athersys on 5 of the 8 factors compared between the two stocks.

How does Athersys compare to Bio-Path?

Athersys (NASDAQ:ATHX) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Athersys' return on equity of 0.00% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Bio-Path	N/A	-2,842.40%	-337.48%

19.4% of Athersys shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 0.0% of Athersys shares are held by company insiders. Comparatively, 0.7% of Bio-Path shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bio-Path has lower revenue, but higher earnings than Athersys. Bio-Path is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

In the previous week, Athersys' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company	Overall Sentiment
Athersys	Neutral
Bio-Path	Neutral

Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

Summary

Athersys beats Bio-Path on 5 of the 9 factors compared between the two stocks.

How does Athersys compare to Graybug Vision?

Athersys (NASDAQ:ATHX) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

19.4% of Athersys shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 0.0% of Athersys shares are owned by company insiders. Comparatively, 7.9% of Graybug Vision shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Athersys' return on equity of 0.00% beat Graybug Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Graybug Vision	N/A	-77.61%	-71.34%

Athersys has a beta of -0.9, suggesting that its share price is 190% less volatile than the broader market. Comparatively, Graybug Vision has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Graybug Vision has higher revenue and earnings than Athersys. Graybug Vision is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A

In the previous week, Athersys' average media sentiment score of 0.00 equaled Graybug Vision'saverage media sentiment score.

Company	Overall Sentiment
Athersys	Neutral
Graybug Vision	Neutral

Summary

Graybug Vision beats Athersys on 6 of the 9 factors compared between the two stocks.

Get Athersys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHX vs. The Competition

Export

Metric	Athersys	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$833K	$965.77M	$6.47B	$11.73B
Dividend Yield	N/A	4.84%	2.67%	5.56%
P/E Ratio	0.00	1.47	24.43	24.35
Price / Sales	N/A	120.41	503.66	108.33
Price / Cash	N/A	20.06	43.20	54.62
Price / Book	N/A	7.97	10.50	6.82
Net Income	-$72.53M	-$4.69M	$3.56B	$337.41M

Athersys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHX Athersys	N/A	N/A	N/A	N/A	$833K	$146K	N/A	24
ORGS Orgenesis	N/A	$0.59 +19.2%	N/A	-81.8%	$3.05M	$662K	N/A	150	Gap Down
CANF Can-Fite BioPharma	1.8009 of 5 stars	$3.16 +1.6%	$42.50 +1,244.9%	-87.3%	$2.07M	$405K	N/A	8
VCNX Vaccinex	N/A	$0.77 -7.6%	N/A	+24.1%	$2.01M	$388K	N/A	40	Gap Down
BPTH Bio-Path	N/A	$0.03 -20.4%	N/A	-80.6%	$1.51M	N/A	N/A	10	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHX) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athersys (ATHX) Competitors